NeilJClendeninnMD

Internal Medicine • Princeville, HI

Hospice & Palliative Medicine, Hematology/Oncology

Physician

Join to view full profile

Are you Dr. Clendeninn?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 16 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
4335 Anini Vista Drive
Princeville, HI 96722
Phone+1 808-294-0660
Is this information wrong?

Summary

Dr. Neil Clendeninn, MD is a board certified internist in Princeville, Hawaii. He is currently licensed to practice medicine in Hawaii, California, and North Carolina.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1985
University of WashingtonResidency, Internal Medicine, 1979 - 1981
New York University School of MedicineClass of 1977

Certifications & Licensure

HI State Medical License 2004 - 2026
CA State Medical License 2005 - 2025
NC State Medical License 1985 - 1999
MD State Medical License 1981 - 1986
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

8 citations
HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Thomas Ottoboni, Michael Lauw, Mary Rose Keller, Matt Cravets, Kimberly Manhard, Neil J. Clendeninn, Barry D. Quart> ;Future Oncology. 2019 Mar 1
9 citations
Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Ralph V. Boccia, Robert B Geller, Neil J. Clendeninn, Thomas Ottoboni> ;Future Oncology. 2019 Jan 1
19 citations
Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Tom Ottoboni, Michael Lauw, Mary Rose Keller, Matt Cravets, Kimberly Manhard, Neil J. Clendeninn, Barry D. Quart> ;Future Oncology. 2018 Jun 6
19 citations
Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Thomas Ottoboni, Mary Rose Keller, Matt Cravets, Neil J. Clendeninn, Barry D. Quart> ;Drug Design, Development and Therapy. 2018 Mar 1
44 citations
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, Diane P. Leffingwell, S. Gail Eckhardt, Lia Gore, Karl D. Lewis, Glen J. Weiss, Ramesh K. Ramanathan, Grace K. Dy, ...> ;Clinical Cancer Research. 2013 Mar 1
10 citations
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
Minaxi Jhawer, Lee S. Rosen, Janet Dancey, Howard S. Hochster, Solomon Hamburg, Margaret A. Tempero, Neil J. Clendeninn, Sridhar Mani> ;Investigational New Drugs. 2006 Sep 7
9 citations
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma
Jordan Berlin, A. Christie King, Kendra D. Tutsch, John W. A. Findlay, Peter C. Kohler, Mary Collier, Neil J. Clendeninn, George Wilding> ;Investigational New Drugs. 1994 Jan 1
1 citations
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion
Richard L. Schilsky, Mark J. Ratain, Linda Janisch, Nicholas J. Vogelzang, V. Sol Lucas, Joshua Ravitch, John A. Hohneker, Neil J. Clendeninn, Richard L. Tuttle> ;Cancer Chemotherapy and Pharmacology. 1993 Jan 1
Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.
Howard H. Bailey, Peter C. Kohler, Richard L. Tuttle, Paul P. Carbone, John A. Hohneker, Neil J. Clendeninn, George Wilding> ;Investigational New Drugs. 1992 Nov 1
10 citations
Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.
Judith D. Schiesel, Matthew Carabasi, Gordon B. Magill, Ephraim S. Casper, Edgar Cheng, Linda D. Marks, Jan Feyzi, Neil J. Clendeninn, Richard V. Smalley> ;Investigational New Drugs. 1992 Jul 1
15 citations
A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer.
Everett E. Vokes, Isaiah W. Dimery, Charlotte Jacobs, Daniel D. Karp, Arturo Molina, Mary Collier, Melody L. Eble, Neil J. Clendeninn> ;Cancer. 1991 May 1
26 citations
Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.
Lynn G. Feun, R Gonzalez, Niramol Savaraj, J Hanlon, M Collier, W A Robinson, N. J. Clendeninn> ;Journal of Clinical Oncology. 1991 Mar 1
15 citations
Phase I Trial of Piritrexim Capsules Using Prolonged, Low-Dose Oral Administration for the Treatment of Advanced Malignancies
Lynn G. Feun, Niramol Savaraj, Pasquale Benedetto, James Hanlon, Kasi S. Sridhar, Mary Collier, Stephen P. Richman, Sam H.T. Liao, Neil J. Clendeninn> ;Journal of the National Cancer Institute. 1991 Jan 2
10 citations
A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
Geoffrey R. Weiss, G. A. Sarosy, Todd D. Shenkenberg, Thomas E. Williams, Neil J. Clendeninn, Daniel D. Von Hoff, Joseph L. Woolley, Sam H.T. Liao, M. Robert Blum> ;European Journal of Cancer & Clinical Oncology. 1989 Dec 1
582 citations
The pharmacology and clinical use of methotrexate
Jacques Jolivet, Kenneth H. Cowan, Gregory A. Curt, Neil J. Clendeninn, Bruce A. Chabner> ;The New England Journal of Medicine. 1983 Nov 3
Join now to see all

Press Mentions

Toragen, Inc. Announces Chief Medical Officer to Drive the Company’s Clinical DevelopmentOctober 7th, 2022